Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Research Objective:At present, there is no standard therapeutic regimen for monoclonal
immunoglobulin light chain (AL) amyloidosis in the world. To compare the efficacy and safety
of the regimens between bortezomib-thalidomide-dexamethasone (BTD) and
bortezomib-cyclophosphamide-dexamethasone (BCD) in the treatment of AL amyloidosis, so as to
provide more clinical evidence for the standard treatment for the disease.
Research Design:This study was designed as a prospective, randomized and controlled clinical
study. Patients who meet the inclusion criteria of this study will be randomized to the BTD
scheme group or BCD scheme group.